RLAY Relay Therapeutics Inc

Price (delayed)

$9.49

Market cap

$1.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.64

Enterprise value

$1.16B

Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.

Highlights
RLAY's gross profit is up by 38% since the previous quarter
Relay Therapeutics's revenue has increased by 38% from the previous quarter
RLAY's quick ratio has soared by 52% year-on-year but it is down by 19% since the previous quarter
The equity has declined by 16% year-on-year

Key stats

What are the main financial stats of RLAY
Market
Shares outstanding
132.74M
Market cap
$1.26B
Enterprise value
$1.16B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.67
Price to sales (P/S)
35.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.74
Earnings
Revenue
$35.33M
EBIT
-$329.12M
EBITDA
-$323.65M
Free cash flow
-$287.5M
Per share
EPS
-$2.64
Free cash flow per share
-$2.2
Book value per share
$5.69
Revenue per share
$0.27
TBVPS
$6.41
Balance sheet
Total assets
$841.44M
Total liabilities
$95.68M
Debt
$52.31M
Equity
$745.76M
Working capital
$732.96M
Liquidity
Debt to equity
0.07
Current ratio
20.73
Quick ratio
20.25
Net debt/EBITDA
0.32
Margins
EBITDA margin
-916.2%
Gross margin
100%
Net margin
-931.6%
Operating margin
-1,045.8%
Efficiency
Return on assets
-37%
Return on equity
-42.7%
Return on invested capital
-44.4%
Return on capital employed
-40.9%
Return on sales
-931.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RLAY stock price

How has the Relay Therapeutics stock price performed over time
Intraday
6.27%
1 week
9.46%
1 month
40.8%
1 year
-20.72%
YTD
-13.81%
QTD
45.55%

Financial performance

How have Relay Therapeutics's revenue and profit performed over time
Revenue
$35.33M
Gross profit
$35.33M
Operating income
-$369.44M
Net income
-$329.12M
Gross margin
100%
Net margin
-931.6%
The net margin has soared by 97% YoY and by 30% from the previous quarter
Relay Therapeutics's operating margin has soared by 96% YoY and by 30% from the previous quarter
RLAY's gross profit is up by 38% since the previous quarter
Relay Therapeutics's revenue has increased by 38% from the previous quarter

Growth

What is Relay Therapeutics's growth rate over time

Valuation

What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
1.67
P/S
35.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.74
The EPS has increased by 6% year-on-year and by 5% since the previous quarter
The equity has declined by 16% year-on-year
The stock's price to sales (P/S) is 92% less than its last 4 quarters average of 436.5
Relay Therapeutics's revenue has increased by 38% from the previous quarter

Efficiency

How efficient is Relay Therapeutics business performance
The return on sales has surged by 97% year-on-year and by 30% since the previous quarter
The ROA is down by 20% YoY
The company's return on equity fell by 20% YoY
The return on invested capital has declined by 15% year-on-year

Dividends

What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLAY.

Financial health

How did Relay Therapeutics financials performed over time
RLAY's current ratio has soared by 52% year-on-year but it is down by 19% since the previous quarter
RLAY's quick ratio has soared by 52% year-on-year but it is down by 19% since the previous quarter
The debt is 93% less than the equity
Relay Therapeutics's debt to equity has increased by 17% YoY
The equity has declined by 16% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.